Moreover, Savona et al. investigated an oral fixed-dose combination of decitabine and cedazuridine, i.e., a CDA inhibitor, in patients with myelodysplastic syndromes or chronic myelomonocytic leukemia [17] and demonstrated favorable decitabine PK through inhibition of CDA. Here, CDA is linked to myelodysplastic syndrome.